Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research[1][2].
Molecular Weight:
(145.2 kDa)
Purity:
99.10
CAS Number:
[872514-65-3]
Target:
c-Met/HGFR
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted